Overview

Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma

Status:
Terminated
Trial end date:
2003-08-30
Target enrollment:
Participant gender:
Summary
Current therapies for Soft Tissue Sarcoma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Soft Tissue Sarcoma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Soft Tissue Sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute